September 14 Sep 14
2018
Friday Fri

Pediatric Grand Rounds (CME): Neuroblastoma Pathology

Hiroyuki Shimada, MD, PhD - Keck School of Medicine USC

The Stanford Department of Pediatrics presents the annual Laurence G. Crowley Distinguished Lectureship.

We are now moving towards a new direction of neuroblastoma pathology research from “Looking for More Prognostic Factors” to “Searching for Actionable/Druggable Targets” according to the concept of precision targeting pathway medicine. 

Session Description:

Peripheral neuroblastic tumors (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma) are composed of biologically different groups presenting with a wide range of clinical behaviors; such as spontaneous regression, tumor maturation, and aggressive progression refractory to intensive treatment.  In order to develop effective/efficient treatment protocols, the patients with this disease are stratified into appropriate risk group (Low, Intermediate, or High) based on the combination of so-called prognostic factors including clinical findings (staging and age at diagnosis), histopathology (International Neuroblastoma Pathology Classification – INPC), and molecular/genetic markers (MYCN oncogene status and chromosomal aberrations).  We are now moving towards a new direction of neuroblastoma pathology research from “Looking for More Prognostic Factors” to “Searching for Actionable/Druggable Targets” according to the concept of precision targeting pathway medicine.  Those targets include MYC-family protein (MYC and MYCN) overexpression and abnormal telomere maintenance/elongation [TERT overexpression and ATRX loss leading to ALT (Alternative Lengthening of Telomere)]. They are immunohistochemically evaluable markers and to be incorporated as new subgroups (MYC, TERT, ALT, and Null) in the future INPC.

Education goals for this session:

  • After the presentation, the audience can tell that peripheral neuroblastic tumors are composed of biologically different group. 
  • After the presentation, the audience can tell a new direction of neuroblastoma pathology research in the precise pathway targeting medicine.
  • After the presentation, the audience can describe highly aggressive MYC-driven neuroblastoma defined by augmented MYCN/MYC protein expression with characteristic nucleolar hypertrophy. 
  • After the presentation, the audience can list potential actionable/druggable targets, such as MYC-family protein overexpression, ALK overexpression, TERT overexpression, and ALT phenotype in the Unfavorable Histology Neuroblastomas. 

Location

Lucile Packard Children's Hospital
725 Welch Road, Auditorium, West Building
Palo Alto, CA 94304
USA

Loading Map...

Lucile Packard Children's Hospital

725 Welch Road, Auditorium, West Building
Palo Alto, CA 94304
Get Directions

Speaker

Hiroyuki Shimada, MD, PhD

Professor of Pathology (Clinical Scholar), Keck School of Medicine USC

  • Founder of the International Neuroblastoma Pathology Classification
  • Established a concept of MYC-driven Neuroblastoma, highly aggressive group of tumors overexpressing either MYCN protein or MYC protein
  •  Winner of the Lotte Strauss Prize and the Enid Gilbert-Barness Prize from the Society for Pedia tric Pathology

CME Credit

Accreditation

The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Stanford University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural and Linguistic Competency

California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency.  The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area. The Stanford University School of Medicine Multicultural Health Portal also contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws. You are encouraged to visit the portal: http://lane.stanford.edu/portals/cultural.html